As of 2025-09-16, the EV/EBITDA ratio of Jounce Therapeutics Inc (JNCE) is 1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. JNCE's latest enterprise value is -51.62 mil USD. JNCE's TTM EBITDA according to its financial statements is -48.70 mil USD. Dividing these 2 quantities gives us the above JNCE EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 6.8x - 12.1x | 8.5x |
| Forward P/E multiples | 13.3x - 19.3x | 19.2x |
| Fair Price | (9.43) - (8.33) | (9.95) |
| Upside | -601.4% - -543.3% | -629.4% |
| Date | EV/EBITDA |